Sigma-Aldrich Corp (fka SIAL)

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

IH Dan (Retired) Admin

04/23/16 3:57 PM

Post #58

http://www.prnewswire.com/news-releases/sigma-aldrich-and-merck-kgaa-darmstadt-germany-obtain-ec-antitrust-approval-and-work-toward-closing-planned-acquisition-300175897.html

ST. LOUIS, Nov. 10, 2015 /PRNewswire/ -- Sigma-Aldrich Corporation (NASDAQ: SIAL) today announced it has secured final approval from the European Commission (EC) on the planned acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany.

MinnieM

04/23/16 3:24 PM

Post #57

A part of MilliporeSigma
http://www.emdmillipore.com/US/en

This board isn't up to date anymore. Merck swallowed Sigma-Aldrich last year.

https://www.sigmaaldrich.com/united-states/about-us.html

Merck KGaA, Darmstadt, Germany, has completed its acquisition of Sigma-Aldrich Corporation. Sigma-Aldrich and Merck KGaA’s existing life science division, EMD Millipore, are now MilliporeSigma. For information on MilliporeSigma, please visit emdmillipore.com. - See more at: https://www.sigmaaldrich.com/united-states/about-us.html#sthash.uw8RV5xy.dpuf

MinnieM

04/23/16 3:18 PM

Post #56

The Making Of MilliporeSigma
http://cen.acs.org/articles/93/web/2015/11/merck-kgaa-completes-sigma-aldrich-acquisition.html

Old article, but, gives a bit of history.

Timothy Smith Free

08/02/15 8:39 AM

Post #55

Sigma-Aldrich (NASDAQ:SIAL): Q2 EPS of $1.01 misses by $0.10.

Revenue of $697M (-0.6% Y/Y) beats by $6.84M.

Timothy Smith Free

05/08/15 10:28 AM

Post #54

Re: #53: @@LaughinPaulRyan - ... HELLO ...

Sigma-Aldrich (NASDAQ:SIAL): Q1 EPS of $1.06 misses by $0.02.

Revenue of $676M (-1.9% Y/Y) misses by $9.23M.

@LaughinPaulRyan Free

12/04/14 8:50 AM

Post #53

... HELLO ...

Great things happening here with an eye towards the future of medicine.

MinnieM

09/20/14 8:36 PM

Post #52

$SIAL - Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership

http://www.genengnews.com/gen-news-highlights/sigma-aldrich-university-of-michigan-partner-to-establish-crispr-core-lab/81250364/

Sigma-Aldrich has partnered with the University of Michigan (UM) Medical School's Vector Core to accelerate gene editing-based research at the UM Medical School.

Vector Core will have access to Sigma-Aldrich’s CRISPR technology, experimental design consultation, and gene editing bioinformaticians. Already underway is an initiative led by UM assistant professor Chad Brenner that involves constructing a large library of Sigma CRISPRs for precision studies of the 100 most common genes that have dysfunctions associated with cancer. The company said it expects Brenner's CRISPR library to support the generation of a dataset about oncogene functions and drug resistance, which could lead to improved decision-making for personalized medical treatment of cancer.

"Since CRIPSR/Cas9 can manipulate genes accurately and efficiently at a genomic scale, instead of just one or a few genes at a time, it is uniquely conducive to screening for gene networks that promote survival of cancer cells,” said Brenner. “Using this technology, we will also be able to define the genes and pathways that drive resistance to existing cancer therapies to aid in the development of more effective combination strategies for patients."

MinnieM

09/11/13 2:12 AM

Post #51

$SIAL - BioReliance Opens New U.S. Clearance Services Laboratories; Completes Global Facility Upgrade Plan

http://online.wsj.com/article/PR-CO-20130904-904364.html

Excerpt:
ST. LOUIS, Sept. 4, 2013 /PRNewswire/ -- Sigma-Aldrich(R) Corporation's (NASDAQ: SIAL) BioReliance(R) (www.bioreliance.com), the biologics and early-development services business under SAFC (www.sigmaaldrich.com/safc), has opened a new Clearance Services facility in Rockville, MD. This world-class facility, commissioned on August 1, 2013, allows BioReliance to offer increased capacity and flexible scheduling while maintaining its core focus on providing industry-leading quality, expertise and value. The new U.S. facility more than doubles the amount of space available to clients to conduct their critical downstream bioprocessing studies.

Designed with input from clients and built to complement BioReliance's global viral clearance services capabilities, the Rockville facility features four large clearance suites with modular layouts that allow for customized laboratory setups. All studies performed at the facility are completely secure and supported by dedicated scientists and state-of-the-art chromatography equipment, such as GE Healthcare's AKTA(R) avant. Every project is fully compliant with applicable global guidelines and regulations, including those from the U.S. Food and Drug Administration and European Medicines Agency. Completed studies receive a consolidated report that includes comprehensive titration and/or process data. BioReliance has already successfully conducted several client studies and quality audits in the new facility.

"Combining our deep knowledge and proven experience with a global investment in modern facilities and equipment enables BioReliance to offer robust validation packages and proprietary CompleteClearance(TM) services to our clients. It's all about simplifying the viral clearance process through an unrivaled combination of scientific expertise, client-focused service and decades of experience," said Archie Cullen, president of BioReliance. "Any time a client comes to work with us, they are assured that their study is expertly designed and performed by personnel that have participated in thousands of successful studies in support of clinical and commercial biopharmaceutical products."

Clients using BioReliance's U.S. facility will have access to a wide range of resources, including personalized modular laboratory suites with spacious, technology-enabled lounges, unique "suite-to-lounge" monitoring, and support from industry-leading personnel.

The Rockville Clearance Services facility investment completes BioReliance's upgrade to its global offering designed to deliver a total client solution and experience. The Stirling, Scotland (U.K.), Clearance Services laboratories were completely renovated and expanded in 2011. To learn more about BioReliance's new Clearance Services facilities, or to inquire about services, please visit: http://www.bioreliance.com/global_clearance_facilities.aspx.

Penny Roger$ Free

04/24/12 7:41 AM

Post #50

Re: #49: @Penny Roger$ - ~ Tuesday! $SIAL ~ Q1 Earnings posted, pending

Penny Roger$ Free

04/24/12 7:41 AM

Post #49

~ Tuesday! $SIAL ~ Q1 Earnings posted, pending or coming soon! In Charts and Links Below!

~ $SIAL ~ Earnings expected on Tuesday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.

http://stockcharts.com/h-sc/ui?s=SIAL&p=D&b=3&g=0&id=p88783918276&a=237480049

http://stockcharts.com/h-sc/ui?s=SIAL&p=W&b=3&g=0&id=p54550695994

~ Google Finance: http://www.google.com/finance?q=SIAL
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=SIAL#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=SIAL+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=SIAL
Finviz: http://finviz.com/quote.ashx?t=SIAL
~ BusyStock: http://busystock.com/i.php?s=SIAL&v=2

<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=SIAL >>>>>>

http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

Penny Roger$ Free

02/09/12 4:09 AM

Post #48

Boardmarked.. Nice board K.C.

Penny Roger$ Free

02/09/12 4:08 AM

Post #47

~ Thurs-Fri $SIAL ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $SIAL ~ Earnings expected on Thursday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.

http://stockcharts.com/h-sc/ui?s=SIAL&p=D&b=3&g=0&id=p88783918276&a=237480049

http://stockcharts.com/h-sc/ui?s=SIAL&p=W&b=3&g=0&id=p54550695994

~ Google Finance: http://www.google.com/finance?q=SIAL
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=SIAL#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=SIAL+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=SIAL
Finviz: http://finviz.com/quote.ashx?t=SIAL
~ BusyStock: http://busystock.com/i.php?s=SIAL&v=2

<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=SIAL >>>>>>

http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

Solar_Express Free

12/15/11 11:25 AM

Post #46

Nanowerk: Nanotechnology Nanomaterial Suppliers..

http://www.nanowerk.com/nanotechnology/nanomaterial/suppliers_cplist.php?country=USA&subcat1=qd

Sigma-Aldrich and Others Listed..

MinnieM

12/05/11 2:13 AM

Post #45

Re: #43: @Stowe - SILK SPINNING THE GENETICALLY MODIFIED WAY

Interesting...

Stowe

11/14/11 5:26 PM

Post #44

LANSING, MI--(Marketwire - November 14, 2011) - Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (PINKSHEETS: KBLB) (the "Company" or "Kraig") announced that researchers at the University of Notre Dame, utilizing customized zinc finger configurations licensed to Kraig from Sigma-Aldrich, succeeded in creating seven or more strains of transgenically modified silkworms./quote]

[url]http://www.thepressreleasewire.com/client/jacksonville/release.jsp?actionFor=1529605/url][tag]insert-text-here[/tag]

Stowe

10/29/11 5:57 PM

Post #43

SILK SPINNING THE GENETICALLY MODIFIED WAY

October 27, 2011 admin No comments

Credit Randy Stewart
Despite the huge potential of genetically modified animals outside of laboratory research, commercialisation of these animals has been extremely limited. Numerous factors, including negative consumer perception, regulatory hurdles, and limitations inherent to classical GM technologies, have kept the majority of GM animal applications within the realm of academic research. However genome editing using zinc finger nucleases could help develop new markets for the future commercialisation of GM animals.

Genetic modification is commonplace throughout the life sciences sector, from fundamental research to pharmaceutical testing. GM cellular and animal models are valuable tools for the study of many chronic diseases, the testing of pharmaceutical compounds and the development of new therapeutic strategies. Genetic modification also offers great benefits in vaccine and biopharmaceutical manufacturing, which rely heavily on the use of GM organisms for biomolecule design and production. Modifying the genome of an organism or cell line allows the incorporation of target biomolecules in specific biological contexts, as well as the transfer of a gene product from a low-producing organism to one that can produce on a commercial scale. These applications have been widely accepted for many years, with countless GM organisms approved for medical manufacturing applications by drug regulators in all major countries. Despite this widespread success within the research and pharmaceutical sectors, the use of GM organisms outside of these markets has been limited.

Despite the lack of broad acceptance for most commercial applications of GM animal products, this technology has been able to gain traction in a few market sectors. The most obvious application has been the commercialisation of transgenic animals for the production of biomolecules for therapeutic use. Cattle, sheep and goats have been used for large-scale production of antibodies, steroids and hormones – most notably insulin – for many years. In 2009, GTC Biotherapeutics received US FDA approval for bioproduction of a recombinant human antithrombin. This product – ATryn – is extracted from the milk of transgenic goats, and is the first approved biopharmaceutical to be produced using genetically engineered animals. Although this is a significant breakthrough for the commercialisation of GM animals, it is still within the pharmaceutical industry, and is a natural progression of existing cell-based technologies. Of potentially greater commercial interest is the extension of genetic engineering outside of this sector, into areas such as food production, textiles and even companion animals.

GM crops have been available in many countries since the early 1990s, and numerous cash crops – including sugar beet, soybean, corn and tomatoes – have been modified to improve resistance to disease, increase the rate of growth or enhance nutritional value. However, cultivation of these transgenic crops is generally tightly regulated, particularly within the European Union, and this, together with negative public opinion, has limited the more widespread development of GM technologies.

Similar to GM crops, many of the animals currently under development are intended to confer disease resistance, an application particularly suited to the use of zinc finger nuclease (ZFN) technology. Many diseases can be treated by the targeted deletion or modification of a host gene. With ZFNs, these targets can be modified with no footprint of genetic engineering. Due to the high costs of raising livestock, another area of focus in developing commercial GM animals has been increasing the rate of growth or size of animals. Among the first GM animals likely to be launched is a fast growing salmon from AquaBounty. The AquAdvantage Salmon is designed to reach market size in half the time of a wild type salmon, reducing costs for fish farmers and limiting the environmental impact of salmon farming by avoiding the need for ocean pens.

Although genetic engineering of animals for food is primarily driven by economic pressures, GM technologies have also been used in the companion animals market. In this sector, genetic modification can be used for practical purposes – such as the creation of hypoallergenic animals or the correction of heritable congenital defects which have arisen though inbreeding – or for purely cosmetic purposes, such as GloFish. The first example of a GM pet, GloFish are fluorescent zebrafish (Danio rerio) that have had genes encoding naturally fluorescent proteins (GFP, YFP, RFP) inserted into their genome. Developed by a group at the National University of Singapore, GloFish were originally created to develop live detection systems for water pollution. They were introduced as pets in the United States in 2003 following over two years of extensive environmental research and consultation. In Europe however, the sale and possession of GloFish is prohibited by rigorous legislation concerning the use of GM technologies.

By allowing precisely targeted insertion of spider genes and concomitant removal of endogenous silkworm silk genes at the same locus, ZFN technology offers the potential for development of transgenic silkworms which will produce native spider silk at commercially viable levels

Perhaps even more interesting from a commercial perspective is the use of GM animals in the manufacture of textiles. Silkworms – actually the larval form of the silkmoth Bombyx mori – have been used for the production of silk for thousands of years, with natural silk still produced by the cultivation of silkworms today. Silkworm cocoons are unwound to create linear silk threads, then re-spun into textiles in much the same way as cotton. Although the applications of silkworm silk are numerous, due to their unique physical and chemical properties, there is also widespread interest in the silks of several other insects.

Spider silk, in particular, offers numerous possibilities within the technical textiles industry, due to its incredible tensile strength and elasticity; characteristics which have not yet been replicated in synthetic materials. Like all insect silks, spider silk fibres consist of repetitive units of protein crystals separated by less structured protein chains. The exact properties and composition of each spider silk vary with its intended function. Major Ampullate or dragline silk, for example, is relatively hydrophobic with very high tensile strength and toughness, as it is used to form the outer rim and spokes of a web. In contrast, hydrophilic capture spiral silks, which form the inner structures of the web, are sticky and highly elastic to effectively entrap prey. This high degree of variability offers enormous potential for the textiles industry, raising the possibility of tailoring the properties of silk to create advanced technical fabrics, for applications such as bulletproof vests, parachute canopies and automobile airbags; biomedical applications, including sutures and tendon and ligament repair; new fabrics, for sportswear and clothing; and even microelectronics.

Although the use of spider silks for microsutures has recently been reported, more widespread application of spider silk technologies is currently limited by the difficulty in producing silks on a commercially viable scale. This is due to the difficulties of rearing spiders in large numbers, due to their highly territorial and cannibalistic nature. As a result, the harvesting of spider silk fibres is extremely time consuming and labour intensive, with production of the only known spider silk garment – an 11 foot by 4 foot shawl made from golden orb spider silk – taking 150 people over five years to produce and costing in excess of £300,000!

To overcome these limitations, and allow future development of spider silk technologies, an alternative strategy for spider silk production is required. This makes spider silk production an obvious candidate for genetic modification, inserting spider silk genes into the genome of other silk-making insects for bioproduction. For example, random insertion of orb spider silk genes into silkworms has allowed production of hybrid spider/silkworm silk using traditional silkworm farming strategies. The resulting hybrid silk contains approximately 10% spider silk and has greater strength and durability than native silkworm silk, raising the possibility of using transgenic silkworms to produce pure spider silks.

Though straightforward in principle, the exchange of native silkworm genes for spider silk genes, alongside more widespread exploitation of genetic engineering, has been limited by the inherent restrictions of conventional GM technologies. The generalised process of modifying an organism requires several capabilities, including:

an ability to synthesise or clone the sequence of interest (if transferring genetic information);
the capacity to grow and maintain a population of the organism of interest;
access to the genome of the organism of interest;
a mechanism to select animals that have received the modification of interest.
While many different techniques exist for accomplishing each of these steps, most GM technologies offer a compromise between the efficiency of the technique and the ability to accurately and precisely target the locus of interest. Viral genomic delivery technologies effectively deliver nucleic acids to cells and organisms, but fall short on ability to target specific regions of the genome, generally only allowing random insertion of genetic material. In comparison, transposase technologies allow a greater degree of targeting, but leave unwanted traces of exogenous DNA in their wake. Other methods involve the introduction of naked DNA into the cell, which results in insertion into the genome at very low frequencies, usually at random, limiting this approach to organisms that can be economically cultivated at high densities and screened in large numbers. Simply put, most techniques for genetic manipulation are random, inefficient and leave a ‘footprint’ of foreign DNA. While this is usually tolerated in basic research, it is not acceptable for most commercial applications, and has been a major hurdle for GM animal technologies to date.

The advent of zinc finger nuclease (ZFN) technology represents a significant breakthrough for commercialisation of GM animal products, offering precisely targeted, efficient genome editing for the first time. Commercially available through Sigma Life Science under the CompoZr brand, this technique can be used to create permanent and heritable changes to an organism of interest.

This high degree of variability offers enormous potential for the textiles industry, raising the possibility of tailoring the properties of silk to create advanced technical fabrics

Credit Nir Nussbaum
ZFNs are a class of engineered DNA binding proteins that facilitate targeted editing of the genome by creating double-strand breaks at user-specified locations. These breaks stimulate the cell’s natural DNA repair mechanisms – homologous recombination (HR) and non-homologous end joining (NHEJ) – which can be exploited to achieve rapid and permanent site-specific modification of the desired genes. While HR can be used to insert foreign DNA sequences, NHEJ allows the cell’s natural processes to create precisely targeted mimics of natural mutations which leave no traces of foreign DNA. Unlike previous techniques, ZFNs offer excellent sequence specificity, binding 24 to 36 base pair target sequences to virtually eliminate off target effects, and are able to achieve modification rates exceeding 20 %, well above rates for most other technologies.

The technique is already being used to create transgenic silkworms for spider silk production. By allowing precisely targeted insertion of spider genes and concomitant removal of endogenous silkworm silk genes at the same locus, ZFN technology offers the potential for development of transgenic silkworms which will produce native spider silk at commercially viable levels.

GM technologies have revolutionised the research world and have great potential in a variety of commercial applications, but have been limited by the inherent restrictions associated with historical GM technologies. The main drawback of these technologies is their inability to accurately and efficiently target genes of interest, instead relying on random insertion of genetic material into host genomes. These limitations result in the need for extensive and costly screening to identify animals with correct transgene expression (without compromising the viability of the animal), and also result in the co-expression of both the transgene and native homologues already present.

The advent of ZFN technology signifies the beginning of an exciting new chapter in the world of genetic modification, allowing precise, targeted and efficient genome editing for the first time. Production of native spider silk using transgenic silkworms is just one example of the potential commercial applications of this innovative technology, taking us one step closer to the reality of industrial scale biomanufacturing and paving the way for an entirely new spectrum of environmentally friendly materials.

Authors:
Joseph Bedell and Brian Buntaine
Commercial Animal Technologies Group, Sigma Advanced Genetic Engineering (SAGE) Labs, Sigma Life Science
www.labnews.co.uk/features/silk-spinning-the-genetically-modified-way/
Thanks king

MinnieM

10/23/11 10:44 PM

Post #42

SIAL chart:

MinnieM

08/03/11 1:04 PM

Post #41

Sigma® Life Science Reaches Milestone in Gene Editing with Increased Affordability for CompoZr® ZFNs and the Expansion of K...

http://ih.advfn.com/p.php?pid=nmona&article=48676044&symbol=SIAL

Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich® (Nasdaq: SIAL), today announced a major breakthrough in the development of its proprietary CompoZr zinc finger nuclease (ZFN) technology with the release of more Knockout ZFNs covering the entire genomes of both mice and rats, while the pricing of products within the CompoZr ZFN portfolio by half. A new dedicated high-throughput manufacturing center, together with advances in ZFN design algorithms and production processes, has led to cost reductions in the development and production for both CompoZr Custom and Knockout ZFNs. This has allowed Sigma Life Science to extend the range of its Knockout ZFNs and to make ZFN technology more affordable to the scientific community. For more information visit www.sigma.com/zfn.

The increased capacity of the new manufacturing facility allows Sigma Life Science to rapidly develop its CompoZr Knockout ZFN portfolio, bringing the advantages of this technology to many previously underserved research fields. The expansion of the Knockout ZFNs for every mouse and rat gene is in its initial phase, which complements the existing range of Knockout ZFNs for the entire human genome. This exciting milestone in genome editing can enable the scientific community to pursue previously unachievable research quickly and easily with validated tools, avoiding the cost, time and uncertainty associated with other techniques.

ZFN technology has been widely recognized as the most efficient and versatile method of genetic engineering for cell lines and whole organisms, offering precisely targeted, permanent and heritable modifications in a fraction of the time required using more traditional technologies. ZFNs have been broadly adopted within the biotechnology and pharmaceutical sectors, but the high cost of designing and manufacturing CompoZr ZFNs has at times limited the research community's access to this technology. To address this issue, Sigma Life Science invested heavily in advancing both its design and production processes to drive down costs and in an effort to help researchers accelerate scientific discovery. The new development and manufacturing facility is expected to ensure affordable pricing for Sigma's complete range of CompoZr ZFN offerings and further extend the scope of this powerful genome editing technology.

David Smoller, Chief Scientific Officer at Sigma Life Science, commented, "Sigma Life Science has reached another milestone in our quest to provide the research community with greater access to ZFN technology. CompoZr ZFNs are now available in multiple formats, multiple species and at more accessible pricing. It is now our objective to continue to drive the development of new applications for CompoZr ZFNs, while maintaining this vital affordability."

Cautionary statement: The foregoing release contains forward-looking statements that can be identified by terminology such as "can enable," "expected," "our objective," or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived there from. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that CompoZr ZFN Technology will assist the Company to achieve any particular levels of revenue in the future. In particular, management's expectations regarding products associated with that CompoZr ZFN Technology could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich business that represents the Company's leadership in innovative biological products and services for the global life science market and offers an array of biologically-rich products and reagents that researchers use in scientific investigation. Product areas include biomolecules, genomics and functional genomics, cells and cell-based assays, transgenics, protein assays, stem cell research, epigenetics and custom services/oligonucleotides. Sigma Life Science also provides an extensive range critical bioessentials like biochemicals, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, amino acids and their derivatives, and cell culture media.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company committed to Enabling Science to Improve the Quality of Life. Its chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 40 countries and has 8,300 employees providing excellent service worldwide. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

Sigma-Aldrich, Sigma and CompoZr are registered trademarks of Sigma-Aldrich Co. LLC.

SOURCE Sigma-Aldrich

MinnieM

07/26/11 9:49 AM

Post #40

Re: #38: @Blind Pig - KarinCA, SIAL is truly a monster company. i

SIAL - Sigma-Aldrich (NASDAQ:SIAL) Q2 2011 Sales Achieve New Quarterly High. Reported Sales and EPS Increase 15% Compared to 2010. ...

http://ih.advfn.com/p.php?pid=nmona&article=48570442&symbol=SIAL

MinnieM

07/22/11 9:54 AM

Post #39

Re: #38: @Blind Pig - KarinCA, SIAL is truly a monster company. i

SIAL - Sigma® Life Science Launches Genetically Modified Human Cell Lines for Breast Cancer Research

http://ih.advfn.com/p.php?pid=nmona&article=48538777&symbol=SIAL

Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich® (Nasdaq: SIAL), today announced the expansion of its CompoZr® Oncology Disease Model portfolio with the release of the first in its collection of breast cancer-specific knockout and knockin cell lines for drug discovery and research. These modified epithelial cell lines are expected to provide researchers with a characterized and known genetic background for basic research and pathway analysis. They are supplied with isogenic parental cell lines to allow high throughput, cell-based screening for drug discovery, target validation and mechanistic studies. For more information, visit www.sigma.com/breastcancercells.

Important breast cancer genes – such as Estrogen Receptor, PTEN and HER2 – have been targeted using Sigma Life Science's proprietary Zinc Finger Nuclease (ZFN) technology, to create stable and heritable genomic knockouts and to provide new cellular models of cancer. These modified human epithelial cell lines, including MCF10A, among others, offer researchers the complete knockout of disease-relevant target gene expression.

Supriya Shivakumar, Global Marketing Manager at Sigma Life Science, said, "These new knockout breast cancer cell lines, created using Sigma's ground-breaking CompoZr® ZFN technology, are expected to be ideal for high throughput screens to determine whether patient-relevant genetic alterations affect drug sensitivity or drug resistance. Researchers now have immediate access to high-quality knockout isogenic human cell lines, which should reduce the costs and labor required for basic research and drug discovery, and could accelerate the development of personalized medicine."

Cautionary statement: The foregoing release contains forward-looking statements that can be identified by terminology such as "expected," "offers," "can," "should" or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived therefrom. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that the CompoZr Oncology Disease Model products described herein will assist the Company to achieve any particular levels of revenue in the future. In particular, management's expectations regarding products associated with CompoZr Oncology Disease Model products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich business that represents the Company's leadership in innovative biological products and services for the global life science market and offers an array of biologically-rich products and reagents that researchers use in scientific investigation. Product areas include biomolecules, genomics and functional genomics, cells and cell-based assays, transgenics, protein assays, stem cell research, epigenetics and custom services/oligonucleotides. Sigma Life Science also provides an extensive range critical bioessentials like biochemicals, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, amino acids and their derivatives, and cell culture media.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company committed to Enabling Science to Improve the Quality of Life. Its chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 40 countries and has 8,000 employees providing excellent service worldwide. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

Sigma-Aldrich, Sigma and CompoZr are registered trademarks of Sigma-Aldrich Co. LLC.

SOURCE Sigma-Aldrich

Blind Pig

07/07/11 2:49 PM

Post #38

Re: #37: @MinnieM - SAFC Launches CHOZN ZFN-modified CHO Cell Lines to

KarinCA, SIAL is truly a monster company. i follow it because of its connection with KBLB. i will be owning some shares soon, along with SGMO. for now i'm all in with KBLB. in time SIALs board will become busier, but most of the posters on the HUB are into micro-companies. SIALs news stream opens doors for other small-caps. just their deal with KBLB has done wonders for KBLB. i try to read all of SIALs news. thankx

MinnieM

07/07/11 12:08 PM

Post #37

Re: #28: @Blind Pig - SIAL recieves raise in price target from Goldman-Sachs. http://www.americanbankingnews.com/2011/04/1

SAFC Launches CHOZN ZFN-modified CHO Cell Lines to Enhance Speed of Bioproduction

http://ih.advfn.com/p.php?pid=nmona&article=48353956&symbol=SIAL

SAFC®, a member of the Sigma-Aldrich® Group (NASDAQ: SIAL), today announced the launch of the first offering in a product line of Zinc Finger Nuclease (ZFN)-modified Chinese Hamster Ovary (CHO) cell lines. Designed for use in the production of biopharmaceuticals, the CHOZN® cell lines are expected to enable customers to reach the market faster and more cost-effectively by reducing timelines commonly associated with early stage biological drug development. The distinctive features of the cell lines should appeal to organizations looking to build a robust and comprehensive therapeutic protein and monoclonal antibody manufacturing platform. Visit www.safcglobal/chozn for additional information on the CHOZN cell lines.

SAFC, a leading provider of custom raw materials and process development services for the biopharmaceutical industry, leveraged its expertise and experience with biopharmaceutical production workflows to engineer the CHOZN series of cell lines to be therapeutic protein manufacturing hosts.

"The CHOZN cell lines have complete traceability and are expected to enable our customers to bring their therapeutic candidates to market more quickly," said Bruce Lehr, SAFC Director of Cell Sciences and Development. "The cell line is robust, and has regulatory-friendly features that we believe will save them time and money."

As part of the first offering of its dynamic cell line series, SAFC is releasing the CHOZN DHFR-/- CHO line for use in the production and manufacture of biological drugs. The DHFR-/- CHO line was developed through CompoZr® ZFN mediated gene editing of the dihydrofolate reductase (DHFR) locus in a robust, extensively characterized and fully documented CHO-K1 host. The new CHOZN® DHFR-/- CHO line allows process development scientists to use any common DHFR expression system for the selection and amplification in a fully traceable CHO-K1 background.

"One of the core areas of focus for SAFC is investing in the development of expertise across emerging technologies that both differentiate us in the marketplace and deliver tangible benefits that support customers in the development of next-generation therapeutics," said Lehr.

For more information on SAFC's CompoZr ZFN offer, visit: www.safcglobal.com/zfnkits

For more information on SAFC's Cell Design Studio (CDS) offer, visit: www.safcglobal.com/cces

The foregoing release contains forward-looking statements that can be identified by terminology such as "expected', "should", "believe" or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived there from. You should not place undue reliance on these statements. There can be no guarantee that the products described in this release will continue to meet the demands of the marketplace. Nor can there be any guarantee that any of these products will achieve any particular levels of revenue in the future. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding these products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About SAFC®: SAFC is the custom manufacturing and services business unit of Sigma-Aldrich Corporation. We are recognized as a top 10 global fine chemical supplier and trusted manufacturer of specialty chemicals and biologics for the life science and high technology industries. Utilizing global "Centers of Excellence" and dedicated manufacturing facilities, SAFC can often resolve development and manufacturing challenges and accelerate the production of custom materials. Our rich portfolio includes high-purity inorganic materials for high technology applications, cell culture products, services for biopharmaceutical manufacturing and biochemical production, and complex, multi-step organic synthesis of APIs and key intermediates. For more information about SAFC, visit www.safcglobal.com.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 40 countries and has 8,000 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning web site at www.sigma-aldrich.com.

SAFC and Sigma-Aldrich are registered trademarks of Sigma-Aldrich Co. LLC.

SOURCE Sigma-Aldrich

MinnieM

06/27/11 11:19 AM

Post #36

Sigma-Aldrich Corporation Announces Q2 2011 Conference Call

http://ih.advfn.com/p.php?pid=nmona&article=48214243&symbol=SIAL

Sigma-Aldrich Corporation will hold its quarterly conference call to discuss second quarter results on Tuesday, July 26, 2011 at 10:00 AM Central Time (11:00 AM Eastern Time).

Date: July 26, 2011
Time: 10:00 AM CT (11:00 AM ET)
Toll Free: 877-266-0483
International: 707-287-9342
Passcode: 37560590
Interested parties may listen via live audio broadcast and view the slide presentation over the Internet available at: http://investor.sigmaaldrich.com/. Users can click the "Webcast" icon to access the file.

Replay will be available July 26, 2011 through August 2, 2011. Replay information is as follows:

Toll Free: 800-642-1687 International: 706-645-9291 Passcode: 37560590

Sigma-Aldrich is a leading Life Science and High Technology company committed to Enabling Science to Improve the Quality of Life. Its chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 40 countries and has 8000 employees providing excellent service worldwide. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com .

CONTACT: Carrie Fields
Investor Relations
314-286-8015
carrie.fields@sial.com

MinnieM

06/07/11 12:04 PM

Post #35

Hydrogen Storage Collaboration Between Sigma-Aldrich and Ilika Technologies to Scale-up and Commercialize Boron Hydride Material

http://ih.advfn.com/p.php?pid=nmona&article=47976398&symbol=SIAL

Hydrogen Storage Collaboration Between Sigma-Aldrich and Ilika Technologies to Scale-up and Commercialize Boron Hydride Materials Materials Show Promise as High Energy, Low Pressure Hydrogen Source
PR Newswire

ST. LOUIS, June 7, 2011

ST. LOUIS, June 7, 2011 /PRNewswire/ -- Aldrich Materials Science, a strategic technology initiative of Sigma-Aldrich Corporation (NASDAQ: SIAL) today announced it has signed an agreement to collaborate on the scale-up and commercialization of next generation hydrogen-storage materials with Ilika plc (AIM:IKA), an advanced cleantech materials discovery company. Both companies believe this enterprise will become a vital component of the energy industry's efforts to develop consumer-friendly hydrogen storage materials for fuel cell and clean combustion technology.

Hydrogen represents an attractive carrier of energy as its combustion or direct conversion to electricity via a fuel cell does not lead to the emission of carbon dioxide. In addition, hydrogen can be used as an alternative energy carrier to battery technology since the energy density of hydrogen can be substantially higher than that of batteries. The main criteria for hydrogen storage for transport purposes, as outlined by the US Freedom Car Initiative (http://www.afdc.energy.gov/afdc/pdfs/freedomcar_plan.pdf), are to supply enough hydrogen to enable a driving range of approximately 500 km, to charge and recharge at near room temperature and to provide hydrogen at rates fast enough for vehicular operation - from cars to trains. Current prototype applications use very high pressure compressed hydrogen or cryogenically cooled liquid hydrogen. These methods consume a significant percentage of the energy content in their compression and conversion and both raise safety concerns. Ilika's storage solution is a solid metal hydride, which exists as a powder stored in a cylinder at moderate pressure and stable at room temperature. When warmed to moderate temperatures, hydrogen is released for use as fuel.

To be economically viable, the target weight percentage of hydrogen stored in such a material has been set at 6% by the US Department of Energy. Current commercially available hydride materials can achieve up to 2.3 weight % of hydrogen. The hydride materials being verified and scaled-up by Aldrich Materials Science can potentially store up to 10 weight % of hydrogen, reversibly.

Commenting on the collaboration, Ilika's CEO, Graeme Purdy, said: "This agreement is a great example of how Ilika, together with our partners, develops innovative materials that solve complex industrial challenges and shares in the commercial upside that these technological advances make possible. Sigma-Aldrich® is a world leader with renowned capability in the field of materials science. Through its Aldrich Materials Science initiative, Sigma-Aldrich possesses state-of-the-art integrated capabilities in hydrogen storage materials for fuel cell technology, including material development (mechanochemistry), manufacturing, application and evaluation, and have agreed to enter into a collaboration to scale-up Ilika's metal-hydride materials. In particular, their mechanochemistry know-how and processing is a proven tool for the preparation of novel materials. We are very pleased to be working with them."

R&D Manager for Aldrich Materials Science, Viktor Balema, added: "We have been very impressed by Ilika's unique high-throughput discovery capabilities, which are very complementary to our scale-up facilities. The collaboration, done as part of our custom research services, creates the unique opportunity to rapidly move from discovery to first commercialization, with the potential of making innovative energy storage materials available to end users in a short period of time. Through collaborative custom research projects, we aim to enable materials innovation in the alternative energy, electronics and biomedical markets."

For further information on Ilika, visit: http://ilika.com/

For further information on Aldrich Materials Science, visit: www.Sigma-Aldrich.com/matsci

Cautionary statement: The foregoing release contains forward-looking statements that can be identified by terminology such as "in the belief", "will become", "can potentially", "plan to" or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived therefrom. You should not place undue reliance on these statements. There can be no guarantee that the collaboration described in this release will result in the development of any products or that such products, if introduced to the market meet the demands of the marketplace. Nor can there be any guarantee that any of these products will achieve any particular levels of revenue in the future. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding these products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company committed to Enabling Science to Improve the Quality of Life. Its chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 40 countries and has 8,000 employees providing excellent service worldwide. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.Sigma-Aldrich.com.

Aldrich and Sigma-Aldrich are registered trademarks of Sigma-Aldrich Biotechnology LP and Sigma-Aldrich Co.

SOURCE Sigma-Aldrich Corporation

MinnieM

06/02/11 1:08 PM

Post #34

Sigma-Aldrich Corporation to Present at Upcoming Investor Conferences

http://ih.advfn.com/p.php?pid=nmona&article=47911290&symbol=SIAL

Sigma-Aldrich Corporation (NASDAQ: SIAL) will be presenting at the following investor conferences in June:

•Jefferies 2011 Global Healthcare Conference on Monday, June 6, 2011, at the Grand Hyatt, New York, NY, presenting at 11:30 AM (Eastern).
•32nd Annual Global Healthcare Conference on Thursday, June 9, 2011, at the Terranea Resort, Rancho Palos Verdes, Los Angeles, CA, presenting at 8:40 AM (Pacific).
•NASDAQ OMX 26th Investor Program on Tuesday, June 21, 2011, at the May Fair Hotel, London, England presenting at 1:15 PM (GMT).
Interested parties may listen via live audio broadcast over the Internet available at http://investor.sigmaaldrich.com/. Users can click the "Webcast" icon to access this file.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company committed to Enabling Science to Improve the Quality of Life. Its chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 40 countries and has 8,000 employees providing excellent service worldwide. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

SOURCE Sigma-Aldrich Corporation

MinnieM

05/05/11 3:33 PM

Post #33

Re: #28: @Blind Pig - SIAL recieves raise in price target from Goldman-Sachs. http://www.americanbankingnews.com/2011/04/1

Sigma® Life Science and King's College London Co-Developing miRNA Target Identification Technology

http://ih.advfn.com/p.php?pid=nmona&article=47544462&symbol=SIAL

Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich® (Nasdaq: SIAL), and King's College London, today announced an exclusive license to develop and commercialize new technology for the identification and validation of microRNA (miRNA) targets in research and clinical diagnostics. For more detailed information, visit www.wherebiobegins.com/targetid.

miRNAs function as critical regulators of gene expression in eukaryotic cells, with more than 1,000 different miRNAs in the human genome already known to play multiple roles in gene regulation. Although the specific targets of most miRNAs are largely unknown, aberrant expression of miRNAs has been implicated in numerous disease states, making them important targets for clinical research in oncology, wound healing and infectious disease.

Currently, identification of miRNA targets is laborious and inefficient, relying on computer algorithms and subsequent validation by in vitro assays. To overcome this research bottleneck, scientists in the Division of Cancer Studies at King's have developed a technology allowing simple, accurate identification and validation of miRNA targets. Dr. Joop Gaken, lead researcher of this project, explained, "The role of miRNAs in cancer is well established, and several miRNAs clearly function as either oncogenes or tumor suppressor genes, although the target genes are unknown in the majority of cases. This new test is expected to enable the straightforward identification of target genes that are strongly regulated by a given miRNA, helping to elucidate important gene regulation events in vivo."

"miRNA research is a rapidly growing field, and this test is expected to be an invaluable asset to commercial and academic researchers working with miRNAs," said Steven Suchyta, Market Segment Manager at Sigma-Aldrich. "We believe that the exclusive license agreement will allow Sigma Life Science and King's College London to work closely together to ensure rapid development of this technology for the benefit of the research community, and underlines our commitment to accelerating scientific discovery through innovative technology."

Cautionary statement: The foregoing release contains forward-looking statements that can be identified by terminology such as "ensures," "is responding to," "is expected to," "will allow," or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived therefrom. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that the miRNA Target Identification Library will continue to meet the demands of the marketplace. Nor can there be any guarantee that any of the products from the miRNA Target Identification Library will achieve any particular levels of revenue in the future. In particular, management's expectations regarding the miRNA Target Identification Library could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich business that represents the Company's leadership in innovative biological products and services for the global life science market and offers an array of biologically-rich products and reagents that researchers use in scientific investigation. Product areas include biomolecules, genomics and functional genomics, cells and cell-based assays, transgenics, protein assays, stem cell research, epigenetics and custom services/oligonucleotides. Sigma Life Science also provides an extensive range critical bioessentials like biochemicals, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, amino acids and their derivatives, and cell culture media.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company committed to Enabling Science to Improve the Quality of Life. Its chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 40 countries and has 8,000 employees providing excellent service worldwide. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

Sigma-Aldrich and Sigma are registered trademarks of Sigma-Aldrich and its affiliate Sigma-Aldrich Biotechnology, L.P.

About King's College London: King's College London is one of the top 25 universities in the world (2010 QS international world rankings), The Sunday Times 'University of the Year 2010/11' and the fourth oldest in England. A research-led university based in the heart of London, it has nearly 23,500 students (of whom nearly 9,000 are graduate students) from 140 countries and approximately 6,000 employees. The College is in the top seven UK universities for research earnings and has an overall annual income of nearly 450 million pounds Sterling. For more information about King's College London, please visit www.kcl.ac.uk

SOURCE Sigma Life Science

MinnieM

04/26/11 10:40 AM

Post #32

Re: #30: @MU_Redskin1 - This partnership between KBLB and SIAL should be

Sigma-Aldrich (NASDAQ:SIAL) Reports Q1 2011 Diluted EPS of $0.97, a 20% Increase Over Q1 2010. Q1 2011 Sales and Earnings Achie

http://ih.advfn.com/p.php?pid=nmona&article=47416355&symbol=SIAL

MU_Redskin1 Free

04/25/11 11:10 AM

Post #30

Re: #27: @tacobellsucks - Kraig Labs(KBLB)/Sigma-Aldrich Nasdaq:SIAL 4/12/2011 News PR

This partnership between KBLB and SIAL should be worth at least a couple bucks to Sigma's bottom line when the spider silk takes off. The industrial textiles and medical implications are huge. imo.

Red

MinnieM

04/19/11 12:52 PM

Post #29

Re: #27: @tacobellsucks - Kraig Labs(KBLB)/Sigma-Aldrich Nasdaq:SIAL 4/12/2011 News PR

Sigma-Aldrich Corporation Annual Shareholder's Meeting

http://ih.advfn.com/p.php?pid=nmona&article=47356240&symbol=SIAL

Sigma-Aldrich Corporation (Nasdaq:SIAL) will hold its Annual Meeting of Shareholders on Tuesday, May 3, 2011, at 11:00 a.m. Central Time (12:00 p.m. Eastern Time).

Date: May 3, 2011
Time: 11:00 AM CT

Webcast and slide presentation can be accessed at Sigma-Aldrich Corporation's website at http://investor.sigmaaldrich.com.

Sigma-Aldrich is a leading Life Science and High Technology company committed to Enabling Science to Improve the Quality of Life. Its chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 40 countries and has 7900 employees providing excellent service worldwide. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

CONTACT: Carrie Fields
Investor Relations
+1 314 2868015
carrie.fields@sial.com

Blind Pig

04/16/11 11:29 PM

Post #28

SIAL recieves raise in price target from Goldman-Sachs. http://www.americanbankingnews.com/2011/04/14/analysts-price-target-changes-for-april-14th-gww-hp-jbht-jpm-line-lstza-mg-mtd-pcs-sgmo-sial-ssw-stj-twc/

tacobellsucks Free

04/15/11 12:32 PM

Post #27

Kraig Labs(KBLB)/Sigma-Aldrich Nasdaq:SIAL 4/12/2011 News PR

Sigma-Aldrich and Kraig Biocraft Laboratories Successfully Negotiate License Agreement

Sigma-Aldrich and Kraig to work together to create the next generation biomaterials.

Sigma-Aldrich Becomes Kraig Shareholder

LANSING , MI --4/12/2011 – Kraig Biocraft Laboratories, Inc. (Pinksheets: KBLB) announced today that the Company has entered into a licensing agreement with biotechnology giant Sigma-Aldrich (NASDAQ: SIAL), Inc.

Kraig has successfully negotiated a license to use Sigma-Aldrich's powerful zinc finger technology to accelerate its scientific research and product development, along with an option to commercialize the resulting biomaterials in the textile and biomedical fields.

“Sigma-Aldrich's proprietary zinc finger technologies are extremely powerful tools which enable very precise genetic targeting,” said Kraig's CEO Kim Thompson. “We are convinced that this technology is the key to creating advanced new products and materials. We believe that when these customized tools are delivered by Sigma in the coming weeks, the technology will enable us to rapidly and precisely target specific gene sequences for the creation of stronger fibers, advanced textiles and new bio-materials.”

“ZFN technology has been revolutionary in genome engineering for various applications, including animal models of disease, engineering of biopharmaceutical production systems, academic research and therapeutics,” said Dr. Joseph Bedell, Director of Sigma's Commercial Animal Technology Group. “Spider silk production is just the first example of a commercial animal application for this exciting technology.”

“Kraig has the utmost confidence in the power of Sigma's zinc finger technology,” said Mr. Thompson. “Sigma's agreeing to provide this technology by virtue of the licensing agreement to Kraig, is a real boost for us, and for the future of bio-materials and spider silk technology. We negotiated this agreement not only to accelerate our development of advanced materials, but also because I believe that Sigma's zinc finger technology will reinforce Kraig's competitive advantage in the field of bio-materials and advanced silk polymers. Kraig Biocraft Laboratories expectation is that the combination of Sigma-Aldrich's revolutionary technology and know-how, coupled with Kraig's proprietary bio-materials technology and know-how, will create synergies that will benefit both companies.

About Sigma-Aldrich

Sigma- Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma- Aldrich operates in 38 countries and has 7,900 employees providing excellent service worldwide. Sigma- Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com .

About Kraig Biocraft Laboratories

Kraig Biocraft Laboratories is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry. For further information please visit www.KraigLabs.com .

Statements in this press release about the company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "hopes," "develops," "researching," "research," "potential," "implications," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact:
Ben Hansel
(720) 288-8495 benh@ttfsco.com

Sigma-Aldrich's release

Sigma ® Life Science and Kraig Biocraft Laboratories to Develop Silkworms for the Production of Spider Silk

Sigma's CompoZr ® ZFN technology expected to enable targeted insertion of spider silk genes and the removal of endogenous silkworm genes

St. Louis, MO. – April 12, 2011 – Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich ® (Nasdaq:SIAL), today announced the signing of an agreement with Kraig Biocraft Laboratories, Inc. (KBLB) to develop genetically modified silkworms for the production of spider silk, using Sigma's proprietary CompoZr Zinc Finger Nuclease (ZFN) technology. The transfer of silk genes from the spider to the silkworm is expected to allow the mass production of silk with enhanced strength and elasticity with potential textiles and biomedical applications, such as sutures, tendon and ligament repair, bulletproof vests, and automobile airbags.

Since the first published sequence of a spider silk gene in 1990, much research has focused on the production of commercially viable spider silk with high tensile strength and elasticity. In 2010 KBLB made an important advance towards this goal, by producing hybrid silkworms with randomly inserted spider silk genes, yielding hybrid spidersilkworm silk with greater strength and durability than native silkworm silk. The precise gene targeting and high efficiency of Sigma's ZFN technology allow s KBLB to build on its revolutionary proof of concept research, by concomitantly targeting the insertion of spider silk genes into the silkworm genome while removing endogenous silkworm silk genes. The resulting transgenic silkworm is expected to be capable of spinning pure spider silk at commercially viable production levels.

“ZFN technology has been revolutionary in genome engineering for various applications, including animal models of disease, engineering of biopharmaceutical production systems, academic research and therapeutics,” said Dr. Joseph Bedell, Director of Sigma Life Science's Commercial Animal Technologies Group. “Spider silk production is just the first example of a potential commercial animal application for this exciting technology, perfectly positioning Sigma Life Science as a leading provider of innovative technologies that are changing the face of science and improving the quality of life.”

Cautionary statement: The foregoing release contains forward-looking statements that can be identified by terminology such as “expected,” "allows," "potential," or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived there from. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that CompoZr Zinc Finger Nuclease technology will assist the Company to achieve any particular levels of revenue in the future. In particular, management's expectations regarding products associated with CompoZr Zinc Finger Nuclease technology, including those related to silk production, could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich business that represents the Company's leadership in innovative biological products and services for the global life science market and offers an array of biologically-rich products and reagents that researchers use in scientific investigation. Product areas include biomolecules, genomics and functional genomics, cells and cell-based assays, transgenics, protein assays, stem cell research, epigenetics and custom services/oligonucleotides. Sigma Life Science also provides an extensive range critical bioessentials like biochemicals, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, amino acids and their derivatives, and cell culture media.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company committed to Enabling Science to Improve the Quality of Life. Its chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 40 countries and has 7 9 00 employees providing excellent service worldwide. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com .

Sigma-Aldrich and Sigma are trademarks of Sigma-Aldrich Biotechnology L.P. and Sigma-Aldrich Co.

MinnieM

04/04/11 1:12 PM

Post #26

Sigma-Aldrich Opens European Headquarters in St. Gallen, Switzerland

http://ih.advfn.com/p.php?pid=nmona&article=47150834&symbol=SIAL

MinnieM

03/17/11 2:07 PM

Post #25

Sigma® Life Science Launches Suite of Knockout Rats to Model Parkinson's Disease

http://ih.advfn.com/p.php?pid=nmona&article=46914335&symbol=SIAL

Sigma® Life Science Launches Suite of Knockout Rats to Model Parkinson's Disease Latest Sigma Advanced Genetic Engineering (SAGE™) Labs Innovation Opens New Frontiers for Research
PR Newswire

ST. LOUIS, March 17, 2011

ST. LOUIS, March 17, 2011 /PRNewswire/ -- Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich® (Nasdaq: SIAL), announced that its SAGE Labs initiative has created a suite of knockout rat models of Parkinson's disease in collaboration with The Michael J. Fox Foundation for Parkinson's Research (MJFF). Developed using the proprietary SAGEspeed™ model creation process, these off-the-shelf rat models represent a breakthrough in Parkinson's disease research, overcoming the inherent limitations of the existing mouse models. For more information, on these animal models visit http://www.sageresearchmodels.com

Knockout rat models offer significant advantages over the existing mouse models, which do not effectively mimic the symptoms of Parkinson's disease in humans. The neuronal circuitry of the rat model more closely imitates that of humans, better demonstrating the disease symptoms, and rats' size and behavior allow researchers to perform a variety of experimental procedures more easily than in mice. In collaboration with MJFF, SAGE Labs has used Sigma Life Science's CompoZr® Zinc Finger Nuclease (ZFN) technology to create a range of knockout rat models specific to Parkinson's disease, based on existing knowledge of the key genes implicated in the disease. This groundbreaking collection of rat models currently includes LRRK2, Parkin, Pink1 and DJ-1 knockouts which will help researchers accelerate investigation of novel therapeutic strategies for Parkinson's disease.

"This collaboration with The Michael J. Fox Foundation for Parkinson's Research highlights the enormous potential of our CompoZr and SAGEspeed technology platforms, and displays our commitment to providing the scientific community with tools for cutting-edge research into diseases that afflict the human population," said Dr. Edward Weinstein, Director of SAGE Labs at Sigma Life Science.

Cautionary statement: The foregoing release contains forward-looking statements that can be identified by terminology such as "represent a major step," "may serve," "opens the doors," "will become" or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived therefrom. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that knockout rats will achieve any particular levels of revenue in the future. In particular, management's expectations regarding knockout rats could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich business that represents the Company's leadership in innovative biological products and services for the global life science market and offers an array of biologically-rich products and reagents that researchers use in scientific investigation. Product areas include biomolecules, genomics and functional genomics, cells and cell-based assays, transgenics, protein assays, stem cell research, epigenetics and custom services/oligonucleotides. Sigma Life Science also provides an extensive range critical bioessentials like biochemicals, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, amino acids and their derivatives, and cell culture media.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company committed to Enabling Science to Improve the Quality of Life. Its chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 40 countries and has 7,900 employees providing excellent service worldwide. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

Sigma-Aldrich, Sigma and CompoZr are registered trademarks of Sigma-Aldrich and its affiliate Sigma-Aldrich Biotechnology, L.P. SAGE and SAGEspeed are trademarks of Sigma-Aldrich and its affiliate Sigma-Aldrich Biotechnology, L.P.

SOURCE Sigma Life Science

MinnieM

02/25/11 1:49 AM

Post #24

Sigma® Life Science Launches Pre-designed CompoZr® Knockout Zinc Finger Nucleases for Entire Human Genome

http://ih.advfn.com/p.php?pid=nmona&article=46615709&symbol=SIAL

Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich® (Nasdaq: SIAL), today announced the release of its pre-designed CompoZr Knockout Zinc Finger Nucleases (ZFNs) technology to knockout any gene in the human genome. The new offer, attractively priced to fit within the budget of a typical laboratory, can generate permanent and heritable gene knockouts in human cell lines within weeks. For more detailed information, visit www.wherebiobegins.com/knockout.

Currently, few laboratories create gene knockouts in human cell lines due to the inefficiencies of the natural cellular homologous recombination system and the investment of time and labor required to screen the resulting cells. In contrast, a wealth of peer-reviewed literature has shown that CompoZr ZFNs efficiently generate human cell lines with precise and stable gene knockouts in a matter of weeks.(1)

"Sigma Life Science has worked diligently to develop predesigned CompoZr Knockout ZFNs for each gene in the human genome to make this ground breaking technology more readily available to the research community," said David Smoller, Chief Scientific Officer of Sigma Life Science. "Researchers can select a ZFN from our library and swiftly knockout their target gene in any human cell line."

In this new offering, Sigma has designed CompoZr ZFNs that will produce a knockout in each gene by inducing a double-strand break at a defined site within the gene's first three exons. This double strand break stimulates the cell's natural DNA repair pathways, resulting in a permanent, site-specific deletion or mutation that disrupts the gene's function. Robust and on-target gene knockout using CompoZr Knockout ZFNs is guaranteed by functional validation prior to shipment and unique enhancements to the DNA-recognition and cleavage ZFN subunits.

All CompoZr Knockout ZFNs can be ordered directly through the Your Favorite Gene powered by Ingenuity (YFG) web portal at www.wherebiobegins.com/yfg.

More sophisticated genetic modifications, such as single nucleotide substitutions, can be generated through Sigma Life Science's CompoZr Custom ZFN Service. The CompoZr Targeted Integration Kit also allows rapid integration and expression of a gene of interest at the well-characterized adeno-associated virus integration site 1 (AAVS1) on human chromosome 19.

Reference

(1) http://www.sigmaaldrich.com/life-science/zinc-finger-nuclease-technology/zfn-references.html

Cautionary statement: The foregoing release contains forward-looking statements that can be identified by terminology such as "expected," "ideally suited" or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived therefrom. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that CompoZr Knockout ZFNs will assist the Company to achieve any particular levels of revenue in the future. In particular, management's expectations regarding products associated with CompoZr Knockout ZFNs could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich business that represents the Company's leadership in innovative biological products and services for the global life science market and offers an array of biologically-rich products and reagents that researchers use in scientific investigation. Product areas include biomolecules, genomics and functional genomics, cells and cell-based assays, transgenics, protein assays, stem cell research, epigenetics and custom services/oligonucleotides. Sigma Life Science also provides an extensive range critical bioessentials like biochemicals, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, amino acids and their derivatives, and cell culture media.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company committed to Enabling Science to Improve the Quality of Life. Its chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 40 countries and has 7,900 employees providing excellent service worldwide. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

Sigma-Aldrich, Sigma and CompoZr are registered trademarks of Sigma-Aldrich Co. and its affiliate Sigma-Aldrich Biotechnology, L.P.

SOURCE Sigma Life Science

MinnieM

02/24/11 2:45 AM

Post #23

Sigma-Aldrich to Present at the Citi 2011 Healthcare Conference on Wednesday, March 2, 2011

http://ih.advfn.com/p.php?pid=nmona&article=46594757&symbol=SIAL

Sigma-Aldrich Corporation (Nasdaq: SIAL) will be presenting at the Citi 2011 Healthcare Conference on Wednesday, March 2nd at 1:30 PM ET in New York, NY. Interested parties may listen via live audio broadcast over the Internet available at http://investor.sigmaaldrich.com/. Users can click the "Webcast" icon to access this file.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,900 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

SOURCE Sigma-Aldrich Corporation

MinnieM

02/17/11 2:38 PM

Post #22

Sigma-Aldrich Announces Organizational Changes
http://ih.advfn.com/p.php?pid=nmona&article=46499307&symbol=SIAL

Sigma-Aldrich® Corporation (Nasdaq: SIAL) announces the following executive leadership appointments intended to more closely align its corporate structure with its strategic plan.

Frank Wicks, President Research, will assume responsibility for the entire portfolio of Research products, including those in Research Essentials, Research Specialties and Research Biotech. This newly combined Research strategic business unit will be responsible for product development and R&D; strategic marketing and branding; and global sourcing and operations strategies. This new organization will better enable the Company to accelerate strategic initiatives in defined key areas of focus: Analytical, Biology and Chemistry with an added emphasis on the fast growing materials science market. Wicks will continue to report to the CEO, Rakesh Sachdev.

David Smoller, formerly President Research Biotech, has been appointed Chief Scientific Officer reporting to Frank Wicks. In this new role, Smoller will be responsible for developing a global R&D strategy and footprint for all research and development initiatives as well as managing our intellectual property portfolio and licensing activity. He will continue to be responsible for developing and commercializing innovative products in emerging technologies of Biology and will leverage his successes in bringing new technologies to market in the area of materials science.

Gerrit van den Dool has been promoted to Vice President and Managing Director US and Canada Region. He will have responsibility for the execution of our Research business strategy as well as supporting the SAFC business in US/Canada including sales, service, distribution, manufacturing and compliance. Prior to relocating from Germany to the US in 2007 to head-up North America sales and Global Accounts, van den Dool successfully led European Sales and Operations. Mike Harris and Eric Green will continue as Vice Presidents and Managing Directors of the Europe, Middle East, Africa (EMEA) and International regions, respectively, and, with van den Dool, will report to the CEO.

Gilles Cottier, President SAFC, will continue to lead the global SAFC organization and report to the CEO. Cottier and his team are responsible for developing and executing the global strategies to enhance the bio-science, custom Pharma, high-tech and supply solutions businesses.

Rakesh Sachdev, President and CEO, stated, "We expect this new organization to significantly enhance the organic growth of our core Research and SAFC businesses. This proven leadership team is best situated to execute the key legs of our growth strategy while driving operational excellence and deploying our financial strength to boost growth through acquisitions."

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, and as key components in pharmaceutical, diagnostic and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals and in industry. Over one million scientists and technologists use our products. Sigma-Aldrich operates in 40 countries and has 7,900 employees providing excellent service worldwide. We are committed to accelerating our Customers' success through leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit our award winning web site at www.sigma-aldrich.com.

SOURCE Sigma-Aldrich Corporation

MinnieM

02/02/11 12:15 PM

Post #21

Sigma Life Science Collaborates with Cofactor Genomics to Develop Publically Available Rat Genome Database

http://ih.advfn.com/p.php?pid=nmona&article=46271366&symbol=SIAL

Sigma Life Science, the innovative biological products and services business of Sigma-Aldrich® (Nasdaq: SIAL), today announced that its SAGE Labs initiative has partnered with Cofactor Genomics in an effort to sequence genomes for six of the most widely used strains of rat. As part of the agreement, Cofactor Genomics plans to generate and analyze sequence data using next generation sequencing systems, while SAGE Labs plans to provide the samples and to host a new, free public database at sageresearchmodels.com in late 2011. The database will include exclusive genomic information and analysis tools.

Currently, the Brown Norway is the only rat strain with a high quality draft sequence available. It was completed by the Rat Genome Consortium in 2004 with funding from the NIH. The draft sequence showed the rat shares nearly every gene implicated in human disease. However, since then, little work has been done, with the last update occurring in November of 2004.

The additional genome sequence provided by SAGE Labs and Cofactor Genomics should enable SAGE Labs to create improved models of human disease for the research community, while helping researchers to better pinpoint the crucial areas of biological difference between rats and humans. The creation of a new, public rat strain database could provide a quantum leap forward for better understanding the genetic basis of disease in humans.

Dr. Edward Weinstein, Director of SAGE Labs at Sigma Life Science, said, "With the costs of whole genome sequencing rapidly coming down, it is now far more feasible to understand the genomes of the most widely used model organisms such as the rat. Sigma Life Science and its SAGE Labs initiative plan to lead the way in revealing these new genomes and making the information publically available."

"This project and collaboration leverages Cofactor's experimental design and analysis expertise to develop a global resource aimed at scientific discovery," said Jon Armstrong, Chief Operating Officer of Cofactor Genomics.

The foregoing release contains forward-looking statements that can be identified by terminology such as "plans to," "should," or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived from the initiative to sequence the rat genome. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that by better understanding the rat genome we will achieve, through our offering of gene-modified rats for sale, any particular levels of revenue in the future. In particular, management's expectations regarding our rat program could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma- Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

For more information on SAGE Labs, please visit http://www.sageresearchmodels.com.

About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich business that represents the Company's leadership in innovative biological products and services for the global life science market and offers an array of biologically-rich products and reagents that researchers use in scientific investigation. Product areas include biomolecules, genomics and functional genomics, cells and cell-based assays, transgenics, protein assays, stem cell research, epigenetics and custom services/oligonucleotides. Sigma Life Science also provides an extensive range of critical bioessentials like biochemicals, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, amino acids and their derivatives, and cell culture media. For more information about Sigma Life Science, please visit our Web sites at Where Bio Begins and Sigma Life Science.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company committed to Enabling Science to Improve the Quality of Life. Its chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 40 countries and has 7,900 employees providing excellent service worldwide. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

About Cofactor Genomics: Cofactor Genomics provides next-generation sequencing and analysis services and cutting-edge genomics solutions to corporate and academic clients worldwide. Cofactor's expertise in experimental design, next-generation sequencing, and advanced analytics provides a foundation for researchers to answer previously unimagined scientific questions. The company uses the most advanced next-generation sequencing platforms available in combination with commercial and proprietary analysis software and pipelines. For more information about Cofactor Genomics, please visit www.cofactorgenomics.com

Sigma-Aldrich and Sigma are trademarks of Sigma-Aldrich Biotechnology L.P. and Sigma-Aldrich Co.

SOURCE Sigma-Aldrich

biomanbaba Deceased

12/21/10 10:19 AM

Post #20

Why am I not here....LMAO....only one reason....I dont have room for another stock in my current portfolio design. If I did and had an extra 60 grand to put to work I would get 1000 of this one
....regards

MinnieM

12/21/10 3:48 AM

Post #19

15 Most Profitable Materials Stocks

SIAL made the list:

http://seekingalpha.com/article/242654-15-most-profitable-materials-stocks?source=email_stocks_and_sectors

MinnieM

11/29/10 3:16 AM

Post #18

Sigma-Aldrich and Nanosys Enter Into Distribution Agreement to Supply Materials to the Research Community

http://ih.advfn.com/p.php?pid=nmona&article=45419873&symbol=SIAL

Sigma-Aldrich (Nasdaq: SIAL) today announced a distribution agreement with Nanosys, Inc., an advanced materials architect. Under the agreement, Sigma-Aldrich, through its Aldrich Materials Science business, is now distributing Nanosys-created silicon nanowires to the global scientific research community for the development of new applications in technologies such as solid-state lighting, electronics and energy storage.

"As Aldrich Materials Science continues to expand its nanomaterials offer, we are pleased to introduce an innovative line of silicon nanowires that includes undoped silicon nanowires as well as the higher conductivity, boron-doped nanowires," said Dr. Kaushik Patel, Product Manager, Aldrich Materials Science. "The applications of these nanowires are, we believe, truly innovative and revolutionary. The fabrication of nanowires is challenging; therefore, a consistent and high-quality supply of these materials from Aldrich Materials Science is expected to enable scientists to accelerate their research to further develop a variety of new high-technology applications that can continue to open up exciting end product markets. In all aspects of the Aldrich Materials Science business, from manufacturing and custom R&D to distribution of materials from leading-edge technology companies such as Nanosys, we strive to fulfill our mission of focusing on materials so that our research customers can focus on results."

"Architected and synthesized at the atomic level, our materials deliver exponential improvements in efficiency and performance," added Jason Hartlove, CEO of Nanosys. "This new distribution agreement with Sigma-Aldrich puts our technology directly into the hands of researchers who are doing exciting work in labs around the world, driving the use of architected material solutions in a new generation of markets and applications."

Nanosys silicon nanowires, which demonstrate semiconductor properties, are comprised of single crystal silicon grown using the vapor liquid solid (VLS) process to a diameter of 150 nm and a length of 20 micrometer. The materials are available undoped or as activated boron-doped p-type silicon nanowires with 1x10(19) /cm(3) doping at ends and a 3 micrometer intrinsic region in the center of the wire. Polydispersed silicon nanowires of various lengths that are designed for use in energy research are also expected to be available beginning January 2011.

Across an increasingly diverse range of applications, silicon nanowires can deliver tangible benefits and significant advances. Examples include:

Electronics applications - sensors can be constructed from nanowire arrays that act as a highly sensitive 'e-skin' which could be used to restore the sense of touch to patients with prosthetic limbs or to enable robotic systems to 'sense' pressure.
Solar cells - Research conducted earlier in 2010 found that fabricating thin films from ordered arrays of vertical silicon nanowires significantly increased the light-trapping properties in solar cells, compared to conventional silicon thin film photovoltaics.
Batteries – Nanowire technology is enabling the production of batteries that are more economical, longer lasting, smaller and more environmentally friendly. Nanowires are used to increase the surface area for electrolyte reaction, thereby enabling greater power in a smaller overall footprint.
To learn more about Aldrich Materials Science, silicon nanowires and other new nanomaterials, please visit http://www.sigma-aldrich.com/newnano.

Cautionary statement: The foregoing release contains forward-looking statements that can be identified by terminology such as "is expected to enable," "can continue to open," "are also expected to be available," "can deliver" or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived therefrom. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that silicon nanowires will achieve any particular levels of revenue in the future. In particular, management's expectations regarding silicon nanowires could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company committed to Enabling Science to Improve the Quality of Life. Its chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 40 countries and has 7,700 employees providing excellent service worldwide. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

About Nanosys, Inc.: Nanosys, Inc. is an advanced material architect, harnessing the fundamental properties of inorganic materials into process ready systems that can integrate into existing manufacturing to produce vastly superior products in lighting, electronic displays and energy storage. In 2010, Nanosys commercialized its quantum dot technology with the QuantumRail(TM), a process-ready component that improves LED backlit display color gamut and efficiency, signing partnerships with LG Innotek and Samsung. Nanosys is currently working with major battery manufacturers to improve lithium-ion battery capacity using its SiNANOde(TM) silicon composite additive that, when added to the anode side, improves capacity by 40 percent. SiNANOde(TM) –enhanced batteries are expected to be available in 2011.

For more information, visit www.nanosysinc.com.

Aldrich and Sigma-Aldrich are trademarks of Sigma-Aldrich Biotechnology LP and Sigma-Aldrich Co. QuantumRail and SiNANOde are trademarks of Nanosys, Inc.

SOURCE Sigma-Aldrich

MinnieM

10/06/10 4:18 PM

Post #17

SAFC® Completes Expansion of High-Potency Fermentation Capabilities at Israel Site
http://ih.advfn.com/p.php?pid=nmona&article=44670068&symbol=SIAL

CPhI Worldwide -- SAFC, a member of the Sigma-Aldrich® Group (Nasdaq: SIAL), today announced the completion of its state-of-the-art expansion of its Jerusalem, Israel facility. The additional capacity expands SAFC's contract manufacturing capabilities in large molecule recombinant proteins and small molecule Active Pharmaceutical Ingredients (APIs) through fermentation, including High Potent APIs (HPAPIs) and secondary metabolites.

The 50,000 sq. ft. cGMP fermentation expansion, which is expected to begin production in October 2010, will focus on niche fermentation of APIs and bulk drugs, producing secondary metabolites (antibiotic-like molecules), cytotoxins and large-molecule proteins. A 30,000 sq. ft. area of the new facility has been designed to be Biosafety Level 2 compliant - enabling manipulation of human pathogens. Capabilities include 1,000 and 4,000-liter tank capacities for bacterial and fungal fermentation, as well as explosion-proof suites.

"Fermentation is a long-standing technology, yet new applications have been recently discovered, including the synthesis of high potency compounds, which is a major growth area currently driving contract manufacturers such as SAFC to look beyond traditional active pharmaceutical ingredient (APIs)," said SAFC President, Gilles Cottier. "The Jerusalem expansion builds upon over 30 years of Sigma-Aldrich experience in the development and manufacture of hundreds of microbial-derived products, and is expected to help SAFC augment its industry-leading strategy of strength and expertise in emerging, highly-specialized technologies and difficult to manufacture products."

At the Jerusalem facility, SAFC employs E.coli, Streptomyces sp., filamentous fungi and yeast, including risk group 2 human pathogens, across a wide product portfolio that includes small organic molecules and peptides, as well as larger molecules such as proteins, lipids and carbohydrates or macromolecules.

"We believe a primary differentiator at our Jerusalem site is our capability to safely manufacture niche small molecule products and biologics such as natural or recombinant proteins," added Cottier. "In addition to having industry-leading techniques, capability and infrastructure to manufacture fermentation derived HPAPIs, the site is a multi-disciplinary, full-service facility offering purification and analytical expertise associated with fermentation technology such as microbiology, organic chemistry, biochemistry and molecular biology."

The foregoing release contains forward-looking statements that can be identified by terminology such as "is expected," "expected to help," or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived therefrom. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any of Sigma-Aldrich's' products will achieve any particular levels of revenue in the future. In particular, management's expectations regarding these products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About SAFC: SAFC is the custom manufacturing and services business unit of Sigma-Aldrich Corporation. We are recognized as a top 10 global fine molecule supplier and trusted manufacturer of specialty chemicals and biologics for the life science and high technology industries. Utilizing global "Centers of Excellence" and dedicated manufacturing facilities, SAFC can resolve development and manufacturing challenges and accelerate the production of custom materials. Our rich portfolio includes high-purity inorganic materials for high technology applications, cell culture products, services for biopharmaceutical manufacturing and biochemical production, and complex, multi-step organic synthesis of APIs and key intermediates. For more information about SAFC, visit www.safcglobal.com.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 40 countries and has 7,600 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

SAFC®, SAFC Hitech® and Sigma-Aldrich® are registered of Sigma-Aldrich Biotechnology L.P. and Sigma-Aldrich Co. Safebridge® is a registered trademark of Safebridge Consultants, Inc.
SOURCE Sigma-Aldrich

MinnieM

10/02/10 6:00 PM

Post #16

I'm wondering if this keeps going? Hmmm...

MinnieM

10/02/10 5:59 PM

Post #15

Filings:

http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0000090185&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

MinnieM

10/02/10 5:59 PM

Post #14

Press Releases:

http://investor.sigmaaldrich.com/releases.cfm

MinnieM

10/02/10 5:58 PM

Post #13

Re: #3: @MinnieM - I've played around with the ibox a bit...will

SIAL chart:

locksflooring Free

05/17/10 7:32 PM

Post #12

Sigma-Aldrich Corporation to Present at the Baird's 2010 Growth Stock Conference on Thursday, May 20, 2010
Date : 05/17/2010 @ 3:11PM
Source : PR Newswire
Stock : Sigma-Aldrich (MM) (SIAL)
Quote : 54.58 0.35 (0.65%) @ 7:22AM

Sigma-Aldrich Corporation to Present at the Baird's 2010 Growth Stock Conference on Thursday, May 20, 2010

Sigma-Aldrich Corporation to Present at the Baird's 2010 Growth Stock Conference on Thursday, May 20, 2010

PR Newswire

ST. LOUIS, May 17

ST. LOUIS, May 17 /PRNewswire-FirstCall/ --

Sigma-Aldrich Corporation (Nasdaq: SIAL) will be presenting at the Baird's 2010 Growth Stock Conference on Thursday, May 20th at 1:15 PM CDT (2:15 PM EDT) in Chicago, IL. Interested parties may listen via live audio broadcast over the Internet available at http://investor.sigmaaldrich.com/. Users can click the "Webcast" icon to access this file.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,600 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

SOURCE Sigma-Aldrich Corporation

locksflooring Free

04/19/10 6:53 AM

Post #11

Sigma(R) Life Science Extends Research Model Portfolio Into Oncology and Carcinogenicity Screening; Introduces World's First p53
Date : 04/19/2010 @ 1:00AM
Source : PR Newswire
Stock : Sigma-Aldrich (MM) (SIAL)
Quote : 55.57 -0.9 (-1.59%) @ 7:22AM

Sigma(R) Life Science Extends Research Model Portfolio Into Oncology and Carcinogenicity Screening; Introduces World's First p53

Sigma(R) Life Science Extends Research Model Portfolio Into Oncology and Carcinogenicity Screening; Introduces World's First p53 Knockout Rat

PR Newswire

ST. LOUIS, April 19

ST. LOUIS, April 19 /PRNewswire-FirstCall/ --

Sigma® Life Science, the innovative biological products and services brand of Sigma-Aldrich® (Nasdaq: SIAL), today introduced the world's first p53 'knockout' rat model, an important development that is expected to, due to the rat's closer physiological and metabolic similarity to humans, significantly improve timelines for carcinogenicity screening and reduce time to market for therapeutics.

The p53 model, being developed through Sigma Advanced Genetic Engineering (SAGE™) Labs (www.sageresearchmodels.com), a Sigma® Life Science initiative, offers the potential for faster and more accurate predictions of how anti-cancer therapeutics work in humans and seeks to increase the understanding of this critical gene. Further characterization of this model is expected to lead to a more comprehensive knowledge of how cancers begin and proliferate. Research applications include early carcinogenicity screening, chemopreventive and chemotherapeutic screening, and p53 pathway studies.

"Over the past twelve months, SAGE Labs has been developing novel rat models, in which specific genes associated with defined disease conditions are deactivated or knocked-out, for use in disease research, especially in areas where the existing mouse models poorly mimic human disease," said Dr. Edward Weinstein, director of SAGE Labs. "The addition of the p53 model extends our offering into oncology research and builds upon our existing portfolio, which targets applications across a number of fields including physiology, endocrinology, neurology and toxicology. Using our proprietary CompoZr™ Zinc Finger Nuclease platform, we are able to develop mouse or rat models without the need for embryonic stem cells. This enables us to create founder animals in about four to five months, which is about a third of the time it would take using a traditional approach."

p53 is a tumor suppressor protein encoded by the TP53 gene and is one of the most widely studied cancer-related genes. Its role in the regulation and stabilization of cell cycle, thus preventing genome mutation, is observed among a wide variety of multicellular organisms, including humans, rodents, frogs and fish. Homozygous rats deficient in the p53 protein are expected to be prone to spontaneous tumors and will be valuable for in vivo screening of carcinogenicity, as well as studying chemopreventive and therapeutic treatment.

The colony of p53 knockout rats is currently being expanded and it is anticipated that cohorts of homozygous p53 knockout animals will be available to ship beginning in July 2010. Parties interested in reserving a cohort to characterize can register their interest or learn more by visiting http://www.sageresearchmodels.com/research-models/priority-partners.

Cautionary statement: The foregoing release contains forward-looking statements that can be identified by terminology such as "is expected to," "significantly improve timelines," "reduce time to market," "offers the potential," "lead to a more comprehensive knowledge" or similar expressions, or by express or implied discussions regarding potential future revenues from products derived therefrom. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that the p53 model will continue to meet the demands of the marketplace. Nor can there be any guarantee that the p53 model will achieve any particular levels of revenue in the future. In particular, management's expectations regarding the p53 model could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich brand that represents Sigma's leadership in innovative biological products and services for the global life science market and offers an array of biologically-rich products and reagents that researchers use in scientific investigation. Product areas include biomolecules, genomics and functional genomics, cells and cell-based assays, transgenics, protein assays, stem cell research, epigenetics and custom services/oligonucleotides. Sigma Life Science also provides an extensive range critical bioessentials like biochemicals, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, amino acids and their derivatives, and cell culture media.

About SAGE Labs: SAGE Labs, a Sigma Life Science initiative, is a world-class provider of research models, including knockout rat models, and extensive support services. Using Sigma's proprietary platform technologies, SAGE specializes in genetic manipulation of in vivo systems for specialized R&D applications. SAGE Labs specializes in the development and characterization of unique, next-generation animal research models featuring specific gene deletions, insertions, repressions and modifications using proprietary CompoZr ZFN (zinc finger nuclease) technology. This genetic manipulation technology works for a variety of animal research models, as well as a wide range of research applications.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. Sigma-Aldrich has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,700 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning website at http://www.sigma-aldrich.com.

CompoZr, SAGEspeed, SAGE, Sigma-Aldrich and Sigma are trademarks of Sigma-Aldrich Biotechnology L.P. and Sigma-Aldrich Co.

SOURCE Sigma-Aldrich

locksflooring Free

03/25/10 6:54 AM

Post #10

Sigma(R) Life Science Joins EMBL Advanced Training Centre Corporate Partnership Programme
Date : 03/25/2010 @ 1:00AM
Source : PR Newswire
Stock : Sigma-Aldrich (MM) (SIAL)
Quote : 53.79 -0.265 (-0.49%) @ 7:22AM

Sigma(R) Life Science Joins EMBL Advanced Training Centre Corporate Partnership Programme

Sigma(R) Life Science Joins EMBL Advanced Training Centre Corporate Partnership Programme

Partnership brings state-of-the-art training in key Sigma biological technologies to the research community

PR Newswire

ST. LOUIS, March 25

ST. LOUIS, March 25 /PRNewswire-FirstCall/ --

Sigma® Life Science, the innovative biological products and services brand of Sigma-Aldrich® (Nasdaq: SIAL), today announced details of a corporate partnership with the European Molecular Biology Laboratory (EMBL) Advanced Training Centre, based in Heidelberg, Germany, that officially opened on March 9, 2010. The partnership brings together EMBL's world-class advanced training program with Sigma Life Science Customer Education Programs, an initiative featuring custom-designed technical workshops and training courses for scientific researchers focused in key technology areas, such as zinc finger nuclease (ZFN) and RNAi technology.

"Our partnership with EMBL provides scientists and researchers at all levels and from all around the world with a unique opportunity to train in key Sigma Life Science technology areas using state-of-the-art teaching laboratories and prerequisite tools," commented Helge Bastian, Vice President of Marketing, Sigma-Aldrich Research Biotech business unit, a Sigma Life Science initiative. "With the launch of this partnership in September 2009, we look forward to developing a compelling and comprehensive series of joint training courses designed not only to meet future challenges in modern science, but to facilitate the networking of young and established scientists, enabling the exchange of ideas to shape the future directions of research."

Joerg Fleckenstein, Senior Manager of Resource Development, EMBL, added: "We are glad to have Sigma Aldrich taking part in the EMBL Advanced Training Centre Corporate Partnership Programme. The courses that are going to be jointly developed and implemented with Sigma Aldrich and other partners will represent a valuable addition to the existing programme of courses and conferences at EMBL."

Sigma Life Science's core mission is to enable researchers to unravel the complex biomolecular interactions within cells, tissues, organs and organisms. The recently launched 'Where Bio Begins' brand and website are generating awareness of the Company's strengths in providing products and technologies that are intended to facilitate scientists' understanding of how diseases develop and how molecules function, providing a single destination where researchers can access deep biological knowledge and market-leading products and technologies. The EMBL partnership enables Sigma Life Science to further support this mission and reinforces the Company's dedication to research and education in biology and molecular life sciences.

For further information on Sigma Life Science's Customer Education programs, visit www.sigma.com/workshop or email techincalworkshops@sial.com. To find out more about Where Bio Begins, check out www.wherebiobegins.com.

About the European Molecular Biology Laboratory: The European Molecular Biology Laboratory is a basic research institute funded by public research monies from 20 member states (Austria, Belgium, Croatia, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden, Switzerland and the United Kingdom) and associate member state Australia. Research at EMBL is conducted by approximately 85 independent groups covering the spectrum of molecular biology. The Laboratory has five units: the main Laboratory in Heidelberg, and Outstations in Hinxton (the European Bioinformatics Institute), Grenoble, Hamburg, and Monterotondo near Rome. The cornerstones of EMBL's mission are: to perform basic research in molecular biology; to train scientists, students and visitors at all levels; to offer vital services to scientists in the member states; to develop new instruments and methods in the life sciences and to actively engage in technology transfer activities.

About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich brand that represents Sigma's leadership in innovative biological products and services for the global life science market and offers an array of biologically-rich products and reagents that researchers use in scientific investigation. Product areas include biomolecules, genomics and functional genomics, cells and cell-based assays, transgenics, protein assays, stem cell research, epigenetics and custom services/oligonucleotides. Sigma Life Science also provides an extensive range critical bioessentials like biochemicals, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, amino acids and their derivatives, and cell culture media.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. Sigma-Aldrich has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,700 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning website at http://www.sigma-aldrich.com.

Sigma-Aldrich, Sigma and Prestige Antibodies are trademarks of Sigma-Aldrich Biotechnology L.P. and Sigma-Aldrich Co.

SOURCE Sigma-Aldrich

Bookmark With :

MinnieM

03/24/10 1:48 AM

Post #9

Re: #8: @locksflooring - SAFC Hitech(R) Well Positioned for High-Brightness LED Manufacturing

Look at that SIAL chart in March...unreal.

locksflooring Free

03/23/10 7:18 AM

Post #8

Re: #7: @MinnieM - Sigma-Aldrich Further Expands In Vivo Biology Offering by

SAFC Hitech(R) Well Positioned for High-Brightness LED Manufacturing Boom With TMG Expansion at Bromborough UK Plant
Date : 03/23/2010 @ 1:00AM
Source : PR Newswire
Stock : Sigma-Aldrich (MM) (SIAL)
Quote : 54.34 -0.37 (-0.68%) @ 7:22AM

SAFC Hitech(R) Well Positioned for High-Brightness LED Manufacturing Boom With TMG Expansion at Bromborough UK Plant

SAFC Hitech(R) Well Positioned for High-Brightness LED Manufacturing Boom With TMG Expansion at Bromborough UK Plant

PR Newswire

ST. LOUIS, March 23

ST. LOUIS, March 23 /PRNewswire-FirstCall/ --

SAFC Hitech®, a business segment within SAFC®, a division of the Sigma-Aldrich® Group (Nasdaq: SIAL), today announced it plans to invest $2m (approximately 1.2m pounds Sterling) in expanding production of trimethylgallium (TMG) at its Bromborough, Wirral, UK manufacturing plant. The investment, which was supported by Wirral Council and The Mersey Partnership (TMP), who helped secure additional funding of 300,000 pounds from the Northwest Regional Development Agency (NWDA), is expected to enable SAFC Hitech to strengthen its position as a leading global supplier of TMG and satisfy the growing demand for the material in the production of high brightness LEDs (HBLEDs) for use in applications such as backlighting in flat panel television sets and energy efficient lighting.

Reducing energy consumption and extending energy efficiency are trends driving the global electronics industry to provide more energy-efficient products and systems. Demand in the lighting industry, for example, has seen improvement with the deployment of LEDs to replace currently ubiquitous systems - incandescent light bulbs, fluorescent lighting and its compact fluorescent lamp (CFL) derivative. As a result, the electronics market is at the start of a phase where mass manufacture of HBLEDs is occurring.

TMG has been manufactured at SAFC Hitech's Bromborough facility for a number of years, primarily for supply to the global semiconductor industry. However, as TMG also fulfills the technical criteria for devices designed for the LED, laser, communication and other markets, the boom in demand for LEDs has led to the conclusion that expanding the plant - with its expertise and specific manufacturing knowledge for this process - was the ideal business solution to meet customer demand. The 300,000 pounds Grant for Business Investment (GBI), which was awarded by the NWDA, is part of 'Solutions for Business', the UK Government's package of publicly-funded business support designed to help companies start and grow.

"Expanding our TMG capacity not only draws on our Bromborough facility's core competencies, but also reinforces Sigma-Aldrich's overall strategy of leveraging proprietary technologies and capabilities into new, fast growing market segments, thus differentiating ourselves and our materials offerings through technical innovation," commented Dr. Geoff Irvine, VP, Business Development, SAFC Hitech. "This investment is expected to accelerate the delivery of TMG to a growing market position and reinforce our position as a leading global manufacturer and distributor for the growing LED market worldwide, as well as create jobs in the area, which is positive news given the current economic climate."

For further information regarding SAFC Hitech's world-class portfolio of products and services, go to www.safchitech.com.

The foregoing release contains forward-looking statements that can be identified by terminology such as "strengthen its position," "satisfy the growing demand," "ideal business solution," "meet customer demand," "create jobs" or similar expressions, or by express or implied discussions regarding potential future revenues from products. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that TMG products will continue to meet the demands of the marketplace. Nor can there be any guarantee that any of these products will achieve any particular levels of revenue in the future. In particular, management's expectations regarding these products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About SAFC Hitech: SAFC Hitech provides a unique chemistry service translating application understanding into performance materials worldwide. Through collaborative partnerships and an integrated approach from research and development, process development and scale up to commercial manufacturing, SAFC Hitech invests in innovation and manufacturing enabling current and future technology needs. Further information can be found at http://www.safchitech.com.

About SAFC: SAFC is the custom manufacturing and services business unit within Sigma-Aldrich that focuses on high-purity inorganics for high technology applications, cell culture products and services for biopharmaceutical manufacturing, biochemical production and the manufacturing of complex, multi-step organic synthesis of APIs and key intermediates. SAFC has manufacturing facilities around the world dedicated to providing manufacturing services for companies requiring a reliable partner to produce their custom manufactured materials. SAFC has four business segments – SAFC Pharma®, SAFC Supply Solutions®, SAFC Biosciences®, and SAFC Hitech® – and had annual sales of over $620 million in 2008. SAFC is considered a top 10 fine chemical company. For more information about SAFC, visit www.safcglobal.com.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,700 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at www.sigma-aldrich.com.

SAFC, SAFC Hitech and Sigma-Aldrich are registered trademarks Sigma-Aldrich Biotechnology L.P. and Sigma-Aldrich Co.

SOURCE Sigma-Aldrich

Older

Sigma-Aldrich Corp (fka SIAL)

Followers	5	Posters	13
Posts (Today)	0	Posts (Total)	58
Created	01/16/10	Type	Free
Moderators

Sigma-Aldrich Corp (Nasdaq: SIAL)

http://www.sigmaaldrich.com/united-states.html

Company Information:

Sigma-Aldrich Corp.
3050 Spruce Street
St. Louis, MO 63103

Phone: 314-771-5765
800-521-8956

CIK: 0000090185

Sigma-Aldrich is a leading Life Science and High Technology company whose biochemical, organic chemical products, kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostics and high technology manufacturing.

Sigma-Aldrich customers include more than 1.3 million scientists and technologists in life science companies, university and government institutions, hospitals and industry. The Company operates in 40 countries and has nearly 9,000 employees whose objective is to provide excellent service worldwide. Sigma-Aldrich is committed to accelerating customer success through innovation and leadership in Life Science and High Technology.

Management:

http://investor.sigmaaldrich.com/management.cfm

Top Institutional Holders:
Ownership Profile: http://investor.sigmaaldrich.com/ownership-profile.cfm

Press Releases:

http://investor.sigmaaldrich.com/releases.cfm

http://finance.yahoo.com/q/h?s=SIAL+Headlines

Filings:

http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0000090185&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Transfer Agent:

Registered Shareholder Contact Information
American Stock Transfer & Trust Company
Shareholder Services Department
6201 15th Street
Brooklyn, NY 11219
Toll Free: (800) 937-5449
Local & International: (718) 921-8124
Email: investors@amstock.com
Web site: http://www.amstock.com

Share Structure:

See SEC filings

Investor Relations:

http://investor.sigmaaldrich.com/

Primary IR Contact
Quintin Lai
Vice President – Investor Relations and Corporate Communications
Email: investorrelations@sial.com
Sigma-Aldrich Corporation
Phone: 314-898-443
Fax: 314-286-7874

" />

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn’t a sign of endorsement.

Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

Board Info

Posts Today	0
Posts (Total)	58
Posters	13
Moderators

New Post

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Sigma-Aldrich Corp (fka SIAL)

Sigma-Aldrich Corp (fka SIAL)

Join the InvestorsHub Community

Sigma-Aldrich Corp (fka SIAL)

Board Info